21 days of mammalian omega-3 fatty acid supplementation improves aspects of neuromuscular function and performance in male athletes compared to olive oil placebo by Evan Lewis et al.
Lewis et al. Journal of the International Society of Sports Nutrition  (2015) 12:28 
DOI 10.1186/s12970-015-0089-4RESEARCH ARTICLE Open Access21 days of mammalian omega-3 fatty acid
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male athletes compared to olive oil placebo
Evan J. H. Lewis1*, Peter W. Radonic2, Thomas M. S. Wolever1 and Greg D. Wells2,3Abstract
Background: Omega-3 polyunsaturated fatty acids (N-3) are essential nutrients for human health and integral
components of neural tissues. There is evidence that N-3 supplementation may benefit exercise performance,
however, no study has investigated the ergogenic potential of N-3 supplementation. Our objective was to
determine the effect of short-term N-3 supplementation on neuromuscular-function and physical-performance in
well-trained athletes.
Methods: Male athletes (n = 30), 25 years (SD 4.6), training 17 h.wk−1 (SD 5) completed this randomized,
placebo-controlled, parallel-design study. At baseline a blood sample was collected, maximal voluntary isometric
contractions (MVC) with electromyography (EMG) recordings were measured, and participants underwent various
performance tests including a Wingate test and 250 kJ time trial (TT) followed by repeated MVC and EMG
measurement. Participants were then randomly assigned to receive N-3 (5 ml seal oil, 375 mg EPA, 230 mg DPA,
510 mg DHA) or placebo (5 ml olive oil) for 21-days after which baseline testing was repeated. The magnitude-based
inference approach was used to estimate the probability that N-3 had a beneficial effect on neuromuscular-function
and performance of at least ±1 %. Data are shown as mean ± 90 % confidence-interval.
Results: Plasma EPA was higher on N-3 than placebo (p = 0.004) but the increases in DPA and DHA were not significant
(p = 0.087, p = 0.058). N-3 supplementation had an unclear effect on MVC force (4.1 ± 6.6 %) but increased vastus
lateralis EMG by 20 ± 18 % vs placebo (very likely beneficial). N-3 supplementation reduced Wingate percent power
drop by 4.76 ± 3.4 % vs placebo (very likely beneficial), but the difference in TT performance was unclear (−1.9 ± 4.8 %).
Conclusion: Our data indicates N-3 PUFA supplementation improved peripheral neuromuscular function and aspects
of fatigue with an unclear effect on central neuromuscular function. Clinical trial registration NCT0201433.
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The ability of skeletal muscles to generate force and resist
fatigue is essential to sport performance. Training adapta-
tions within the neuromuscular and skeletal muscle sys-
tems modulate muscle force generating capacity and the
resistance to fatigue. Much investigation has occurred to
determine the effect of nutritional supplements on the* Correspondence: evan.lewis@utoronto.ca
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protein supplementation) and methods to support endur-
ance performance (e.g., carbohydrate loading). To date,
however, there has been limited investigation on the effect
of nutritional supplements on the neuromuscular system.
Central and peripheral nerves are comprised of fatty acids
which are predominantly polyunsaturated [1]. Omega-3
(N-3) polyunsaturated fatty acids (PUFAs) are an integral
component of neurons, nerve endings, myelin and muscle
membranes [1]. N-3 PUFAs are essential nutrients which
must be provided by the diet due to the inability of theicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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PUFA is alpha linoleic acid (ALA; 18:3) found in seeds and
nuts. Eicosapentaenoic acid (EPA; 20:5) and docosahexae-
noic acid (DHA; 22–6) are longer chain N-3 PUFAs found
in marine sources (e.g., fatty fish, seal). Studies on the
effects of N-3 PUFA supplementation have predominantly
focused on their potential ability to reduce cardiovascu-
lar risk factors [2]; however, there is growing evidence
that N-3 PUFAs might support neural function [3, 4]
and adaptations to exercise [5, 6]. Deficiencies in diet-
ary N-3 PUFAs lead to reduced Na+/K+ ATPase activity
and higher stimulation intensity for signal conduction [1].
In contrast, N-3 PUFA supplementation in different clin-
ical and applied settings has enhanced nerve conduction
velocity [3], membrane fluidity, sensitivity to acetylcholine
[7] and also reduced post-exercise inflammation [5, 8].
The effect of N-3 PUFA supplementation on neuro-
muscular and physical adaptations to resistance training
was studied in postmenopausal sedentary women who
were randomly assigned to one of 3 groups: N-3 PUFA
supplementation for 60-days followed by 90-days resist-
ance training with N-3 PUFA supplementation (2 g.d−1
of fish oil), resistance training with N-3 PUFA supple-
mentation or resistance training with no supplementa-
tion [6]. Supplementation without training over 60-days
had no effect neuromuscular function or physical tests.
After training all groups showed improvements in neuro-
muscular function and physical test; however, the N-3
PUFA groups showed significantly greater quadriceps peak
toque and muscle EMG activation and the time delay be-
tween increased muscle electrical activity and contraction
onset was decreased. These findings provide evidence of
the ergogenic potential of this nutritional supplement.Fig. 1 Experimental designSince Lui et al. [9] found that N-3 PUFA were incorpo-
rated into muscle membrane after 21-days of supple-
mentation, we hypothesized that 21-days of N-3 PUFA
supplementation would have an effect on neuromuscu-
lar function and physical performance.
Therefore, our objective was to determine if short-
term N-3 PUFA supplementation has an ergogenic effect
through adaptations in the neuromuscular system. The
primary endpoint of this study was change in quadriceps
maximal voluntary contraction force. The secondary end-
points were change in muscle activation during quadriceps
maximal voluntary contractions and a series of perform-
ance tests.
Methods
Thirty-one healthy male athletes were recruited for this
parallel design, placebo controlled study. A study over-
view is shown in Fig. 1. Participant’s descriptive charac-
teristics are given in Table 1. All competed in summer
Olympic sports (e.g., rowing, sailing, triathlon, running)
that require well developed strength-endurance and en-
durance. Participants were screened for eligibility based
on sport specific competitive history (>2 years), training
hours per week (>12 h), performing back squats as part of
their regular training and not consuming any form of N-3
PUFA supplement or consuming fish ≥ 3 times per week
for 4-weeks prior to beginning the study. The PAR-Q ex-
ercise readiness questionnaire was used for medical
screening (www.csep.ca/english/view.asp?x=698). All par-
ticipants were informed of study procedure and provided
written consent. Approval for this project was obtained
from the University of Toronto Research Ethics Board.
Table 1 Descriptive data for study participants in the omega-3
supplementation group (N-3 PUFA) and placebo group.
Independent t-test determined no difference between groups
Measure N-3 PUFA Placebo p
(n = 18) (n = 12)
Height (cm) 180.3 ± 7.5 180.0 ± 7.7 0.91
Weight (kg) 79.8 ± 8.0 80.2 ± 10.8 0.69
Age (y) 23.7 ± 4.9 26.0 ± 3.0 0.21
Body Fat (%) 12.4 ± 3.3 12.9 ± 4.4 0.74
VO2max (ml . kg-1 . min−1) 49.3 ± 14.2 48.9 ± 3.4 0.93
10RM Squat Max (kg) 92.7 ± 23.2 97.7 ± 16.8 0.40
Watt max 350 ± 47.4 345 ± 35.2 0.86
Training (h . wk−1) 17 ± 6 16 ± 5 0.64
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Height, weight and body fat percentage (Omron Fat
Loss Monitor, model HBF-306CAN, Omron Healthcare,
Bannockburn, Illinois) were measured wearing lightweight
shorts. After a 10-min cycling warm-up at 80 W, partici-
pants were fitted to a custom-made isometric dynamom-
eter. Velcro straps were used to restrain the chest and
hips. Quadriceps muscle force was measured from a load
cell (SM-500-I9; Durham Instruments, Pickering, Canada)
attached in series to the malleolus of the right ankle. The
knee and trunk-thigh angle was fixed at 90°. Force mea-
surements were recorded using a PowerLab 8/35 (ADIn-
struments, Colorado Springs, CO).
Neuromuscular testing
Electrical stimulations
Stimulations of the femoral nerve were delivered from a
high-voltage (400 V) constant current stimulator (Bio-
pac, BSLSTMA, Santa Barbara, California), controlled by
a custom designed program (LabChart 7, ADInstruments,
Colorado Springs, CO, USA). A square wave, 1-ms stimu-
lation was delivered from a cathode (10 mm diameter)
(Kendall 100, Covidien, Saint-Laurant, Quebec, Canada)
placed over the femoral nerve at the femoral triangle be-
neath the inguinal ligament. The anode (5 x 10 cm, DJO,
Vista, CA, USA) was on the lower portion of the gluteal
fold opposite to the cathode. Determination of optimal
stimulation intensity (67.6 ± 14.4 mA; range 41.5–89.6)
was achieved by increasing stimulation intensity until a
further 5 mA increase did not alter peak quadriceps twitch
force and vastus lateralis M-wave amplitude.
Maximal voluntary contractions
Maximal voluntary isometric contraction (MVC) was
used to determine peak muscle force from the dominant
quadriceps. During each neuromuscular testing session,
three 5-s MVCs were performed, each separated by 1-
min rest. Participants were strongly encouraged duringeach trial. The best MVC was used for measurement of
peak muscle force. The rate of force development (RFD)
was calculated for each MVC and averaged. This was
performed using a custom analysis program (Matlab 6.0;
Mathworks Inc.) and defined as the slope of the force
time curve between 20 and 80 % of peak force [6].
Maximal quadriceps activation
A superimposed high-frequency doublet (100 Hz; 10 ms
inter-stimulus interval) was given at 2.5-s into the MVC
and at 5-s after the contraction with the muscle in a po-
tentiated state. Stimulation intensity was 120 % of the
measured optimal stimulation intensity to ensure supra-
maximal stimulation during the MVCs. The ratio of the
amplitude of the superimposed twitch during the MVC
over the potentiated twitch was used to calculate volun-
tary activation as follows:
VA %ð Þ ¼ 1 – superimposed twitch = potentiated twitchð Þ x 100
Electromyographic recordings
Skin on the vastus lateralis (VL) and the patella was
shaved free of hair, lightly abraded with sandpaper and
cleaned with alcohol to ensure low impedance (Z <5
kΩ). VL EMG signal was recorded using Ag-AgCl elec-
trodes (Kendall 100, Covidien, Saint-Laurant, Quebec,
Canada; inter-electrode distance of 25 mm) place length-
wise over the mid-belly of the muscle with the reference
electrode placed over the patella [10]. EMG measurements
were recorded at 2 kHz, using PowerLab 8/35 (ADInstru-
ments, Colorado Springs, CO, USA). EMG signal was
amplified with a Dual BioAmp amplifier (ADInstruments,
Colorado Springs, CO, USA; bandwidth frequency 10–
500 Hz input impedance 200 MΩ, common mode rejec-
tion ratio = 85 dB, gain = ±1 %), transmitted to a PC and
analyzed using a custom analysis program (Matlab 6.0;
Mathworks Inc.).
Muscle activation was determined by calculating the
EMG root mean square (RMS) from when muscle force
began to plateau until immediately before the superim-
posed stimulation. RMS was averaged over 0.2-s periods.
The mean of all three MVC was used for determining
change. All RMS values were normalized to the pre-Visit 1.
The electromechanical delay (EMD) was calculated
from the time difference from the increase in quadriceps
EMG activity and force >10 standard deviations from
resting baseline. This calculation was performed in our
custom Matlab analysis program.
Determination of back squat 10 repetition maximum
After a series of submaximal warm-up sets, participants
selected a weight thought to be their 10RM max based
on current training weights. If the participant thought
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couraged to stop and additional weight was added using
the methods of McLester et al. [11]. This process contin-
ued until a weight the participant could lift for 10 repeti-
tions was determined. To standardize squat depth, an
elastic band was tied across the back of the squat rack
such that participants’ gluteal muscles would touch the
band when the femur was parallel to the ground. Repeti-
tion only counted when contact was made with the band
and band height was measured and kept constant for all
visits.
Maximal oxygen uptake
Participants’ aerobic capacity was determined using
breath-by-breath gas-analysis (MetaMax 3B, CORTEX,
Leipzig, Germany) during an incremental cycling test on
an ergometer (Lode Excalibur, Groningen, Netherlands).
Resistance was set at 50 W, 100 W and 150 W for two
minutes each before increasing by 25 W per minute
thereafter. VO2max was determined as the highest val-
ued achieved over a 20-s period. Watt max was deter-
mined from the stage at which participants’ cadence
dropped below 50 rpm.
Experimental protocol
The experimental protocol consisted of two identical
testing sessions separated by 21-days of supplementa-
tion. Neuromuscular testing occurred before and after a
series of performance tests to examine changes in
neuromuscular function, performance and neuromuscu-
lar fatigue respectively.
Visit 1
Participants returned to the lab at least 48 h after com-
pleting the pre-experimental procedures. Participants
were then weighed to determine Wingate test resistance,
before warming-up on a cycling ergometer (Lode Excali-
bur, Groningen, Netherlands) for 10-min at 80 W.
Neuromuscular testing (pre-Visit 1) was then performed
as described above. Next participants were allowed to
stretch before performing 3 maximal squat jumps and
countermovement jumps on a force plate (AccuPower
ACP, AMTI, Watertown, MA, USA) to measure jump
height using to the manufacturers software (AccuPower
v1.6.3, AMTI, Waterdown, MA, USA).
After 5-min rest, participants completed as many
pushups as possible in 1-min, were given 1-min rest
and then repeated the test a second time. Participants
entered a pushup position with elbows at 90° flexion
and an elastic band was placed in contact with chest
to denote minimum depth. 1-min rest was given before
repeating the protocol. This assessment was interpreted
as a measure of upper-body strength and strength
endurance.After a 5 min break participants began to warm-up for
the back squats by performing 4-6reps at 20 %, 40 %,
60 %, 80 % of their 10RM max before performing the
maximum number of repetitions at 100 % of the prede-
termined 10RM max squat weight.
Participants cycled against light resistance for 10 min
before performing a 30 s Wingate test (Monark 894,
Vansbro, Sweden) at 7.5 % of bodyweight [12]. Peak
power, average power and power drop (%) were recorded.
Participants recovered for 20-min with low intensity
cycling before completing, a 250 kJ cycling time trial
(Lode Excalibur, Groningen, Netherlands). The bike was
set in a pedaling-dependent with power varied by ca-
dence [13]. Resistance was set using 75 % of maximum
power reached in the VO2max test according to the
methods of Jeukendrup et al. [13]. Participants received
no verbal feedback during the time trial regarding the
distance they had covered and were could only see work
completed as an indication of distance travelled. A
standing fan was set at the same speed to reduce ther-
mal stress.
As soon as reasonably possible after the time trial, par-
ticipants returned to the isometric dynamometer to repeat
neuromuscular testing (post-Visit 1). At the completion of
testing, participants were given their randomly assigned
supplement in a sealed opaque envelope.
Visit 2
Participants were asked to refrain from training for 24 h
prior, to control for athletic recovery. All procedures
were identical to Visit 1. Participants were not informed
of prior test performances to ensure that their perform-
ance was not artificially enhanced through mental self-
competition.
Training and dietary controls
Participants were recruited during their regular training
season to ensure constant levels of activity. For the dur-
ation of the study, participants were instructed to main-
tain normal level of training, with the exception of
resting for 24-h prior to each testing session. Participants
were instructed to refrain from consuming >3 servings of
fish per week, in addition to any non-supplied omega-3
supplements. At the beginning of Visit 1, participants
completed a 24-h diet record. This was scanned and sent
back to each participant prior to Visit 2 to ensure the
same foods were eaten prior to each test. All testing took
place at the same time of day to avoid temporal variation.
Omega-3 supplementations
For 21-days, participants consumed 5 mL of seal oil N-3
PUFA (5000 mg N-3 PUFA, 375 mg EPA, 230 mg DPA,
510 mg DHA and with 1000 IU vitamin D3) (Auum Inc.,
Timmons, On) or 5 mL olive oil (Bertolli, Mississauga,
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instructed to take 2–2.5 mL servings orally twice daily,
and to let the oil remain in the mouth for 1-min before
swallowing to allow for sublingual absorption [14].
Seal oil was chosen as the source of experimental N-3
supplement for this study because mammalian (seal) tri-
acylglycerol molecules have N-3 PUFA fats primarily in
the sn-1 and sn-3 positions, as opposed to the sn-2 pos-
ition of fish oil N-3 PUFA [15, 16]. Fats in the sn-3 pos-
ition are preferentially cleaved by sublingual lipases, and
the sn-1 fat is cleaved in the small intestine, while the
sn-2 fatty acid is left for later esterification [14, 17].
These structural differences are thought to enable chylo-
microns and chylomicron remnants containing mamma-
lian N-3 PUFA to have a higher rate of clearance from
the blood compared to fish oil intake [18].
Randomization and concealment
Participants were assigned a sequential study ID based
on their enrollment. Treatment assignment (n-3 PUFA
or placebo) was determined from a computer generated
random number sequence. Supplement bottles were
then sealed in opaque envelopes and labeled with par-
ticipant ID by a researcher not involved in the study.
Participants received their supplement at the end of visit
1. Study researchers were unblinded after plasma n-3
analysis was completed.
Blood sampling
A resting 8 mL blood sample from the antecubital vein
was collected into K3-EDTA Vacutainer tubes (BD
Vacutainer, Mississauga, Canada) at the beginning of
Visit 1 and 2. Samples were centrifuged (3000 rpm for
15 min at 4 °C). Plasma samples were collected and
stored at −80 °C for later analysis of plasma N-3 PUFA
concentration.
Lipid extraction and gas chromatography-flame ionization
detection
All lipid extraction techniques have been previously de-
scribed by Chen et al. [19]. To extract total lipids, Folch,
Lees, and Sloane Stanley’s method was applied by use of
chloroform: methanol: 0.88 % KCl (2: 1: 0.75 by vol.)
Total lipid extraction (TLE) with known quantity of hep-
tadecanoic acid (17:0) was heated for 1 h at 100 °C with
14 % boron trifluoridemethanol to convert to fatty acid
methyl esters (FAME; ester-linked fatty acids). Gas
chromatography-flame ionization detection (GC-FID)
was used to quantify FAME.
A Varian-430 gas chromatograph (Varian, Lake Forest,
CA, USA) with a Varian FactorFour capillary column
(VF-23 ms; 30 m · 0.25 mm i.d. · 0.25 lm film thickness)
and an FID was used to analyze FAME injected in split-
less mode. Injector and detector ports were set at 250 °Cand helium carrier gas was set at a constant flow rate of
0.7 mL/min. A specific temperature program was used
during FAME elution, it was set at 50 °C for 2 min,
slowly increasing by 20 °C/min, and held at 170 °C for
1 min, then at 3 °C/min and held at 212 °C for 5 min to
complete the run at 28 min. Retention times of authen-
tic FAME standards (Nu-Chek Prep, Inc., Elysian, MN,
USA) were used to identify peaks. Internal standard
(17:0) peaks were compared to phospholipids peaks to
calculate fatty acid concentrations, with final values
expressed in nmol/g brain. Protocol for GC-FID was
adopted from Chen et al. [19] where it is well described.
Statistical analyses
This trial was registered at clinicaltrials.gov (NCT0201433)
with statistical analysis of repeated measures ANOVA on
all neuromuscular and performance measurements. After
analysis had begun we became aware of the magnitude-
based inferences analysis approach [20]. The authors de-
termined this approach was more appropriate given our
sample size and population of interest.
The standardized difference in means of neuromuscu-
lar measures was compared as follows: pre-Visit 1 to
pre-Visit 2 and pre-Visit 2 to post-Visit 2. As well the
standardized difference in means of performance tests
from Visit-1 and Visit-2 were compared using pooled
standard deviation as previously described by our lab
[21]. The difference between time points was examined
quantitatively using magnitude based inferences as de-
scribed by Hopkins et al. [20].
A threshold of ±1.0 % was set as threshold for beneficial
or harmful effects on performance as previously described
[22]. The effect of supplementation was interpreted as un-
clear when the odds ratio (OR) of benefit ≥ harm was 66.
This corresponds with an effect that is possibly beneficial
(25 % chance of benefit) and most unlikely harmful (0.5 %
risk of harm) [22].
The inference was generated from the confidence
limits derived from the p-value associated with the effect
and the magnitude of the difference in means such that
a probability that the true value falls within the 90 %
confidence interval corresponds with a qualitative infer-
ence of a 0 % “most unlikely” effect; 0.5 % “very un-
likely”; 5 % “unlikely”; 25 % possibly; 75 % likely; 95 %
likely; 99.5 % very likely; 100 % most likely. Where confi-
dence intervals included values that were both positive
and negative, OR are used to interpret if findings are
meaningful and discussed further. Raw data is presented
as mean ± SD for N-3 PUFA and PLA groups respect-
ively. Interpreted data is presented as mean ± 90 % CI
with corresponding qualitative inference and OR where
appropriate.
Changes in blood N-3 PUFA concentration were ana-
lyzed using a repeated measures-ANOVA (Group x Time)
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using an unpaired t-test (SPSS v21, Armonk, NY). Signifi-
cance was set at p <0.05.
Results
One participant was unable to complete Visit 2 due to
competition related travel. His data was removed from
analysis and final analysis was performed with an n = 30.
When baseline characteristics were compared, the ex-
perimental N-3 PUFA and placebo groups were not dif-
ferent from each other.
Neuromuscular measurements
MVC force
On N-3 PUFA supplement quadriceps MVC force in-
creased from 643 ± 144 to 670 ± 175 N (4.1 %), while on
placebo force increased from 677 ± 107 to 683 ± 154
(0.03 %) (Fig. 2). This represents an unclear change of
(4.1 % ± 6.6; OR = 30). When MVC force was compared
from pre-Visit 2 to post-Visit 2, there was a similar de-
crease in force of −20.3 % and −21.2 % representing an
unclear difference (0.95 % ± 7.5; OR = 2). Similarly, there
was an unclear difference in force between post-Visit 1
and post-Visit 2 (0.90 % ± 8.6; OR = 2).
Rate of force development
Quadriceps RFD was measured during each MVC and av-
eraged. On N-3 PUFA supplement MVC force increased
from 2376 ± 709 N.s−1 to 2522 ± 929 (7.6 %), while on
placebo 2101 ± 608 N.s−1 to 2354 ± 700 (17.1 %). This rep-
resents an unclear difference (9.5 % ± 22; OR = 11). Com-
parison of RFD from pre-Visit 2 to post-Visit 2 showed anFig. 2 Change in quadriceps maximal voluntary contraction (MVC) force is shsimilar change of −16.2 % ± 3.9 and −22.9 % ± 29.6 repre-
senting an unclear difference between groups (−6.7 % ±
14; OR = 15). When post-Visit 1 and post-Visit 2 were
compared the N-3 PUFA group was −1.4 % ± 23.6 lower
and PLA was 14.6 % ± 37.5 higher, representing a likely
harmful effect (−16.0 % ± 19.0; OR = 0).
Electromyography and electromyography delay
Quadriceps muscle activation was calculated from the
RMS EMG signal collected from the VL and normalized
to pre-Visit 1 (Fig. 3). Participants on N-3 PUFA supple-
ment increased muscle activation 9.0 % ± 37.8, while on
placebo EMG decreased 12.9 % ± 19.4. This represents a
very likely benefit (22.0 % ± 20.0; OR = 763). When RMS
was compared from pre-Visit 2 to post-Visit 2, N-3
PUFAs had a likely harmful effect compared to placebo
(−11.3 % ± 12; OR = 0), while the change between post-
Visit 1 and post-Visit 2 represented an unclear difference
(5.9 % ± 3.9; OR = 2).
On N-3 PUFA participants’ EMD increased from 0.053 ±
0.014 s to 0.055 ± 0.019 (16.5 %), while on placebo EMD
was lower 0.050 ± 0.020 s to 0.042 ± 0.018 (−0.85 %). This
represents an unclear difference (17.3 % ± 39.0; OR = 11).
Comparison of EMD change between pre-Visit 2 to post-
Visit 2 showed a likely beneficial effect of N-3 PUFA
(−35.3 % ± 35.1; OR = 361), while there was an unclear dif-
ference between post-Visit 1 and post-Visit 2 (3.6 % ± 28.0;
OR = 2).
Voluntary activation
Maximal quadriceps activation was tested using the
interpolated twitch technique during each MVC andown as percent change from pre-visit 1. Data are shown as mean ± SD
Fig. 3 Change in vastus lateralis (VL) EMG RMS is shown as percent change from pre-Visit 1. *Very likely beneficial increase compared to placebo.
+ Very likely harmful effect compared to placebo. Data are shown as mean ± SD
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creased from 91.1 % ± 7.5 to 91.8 % ± 5. 6 (1.3 %),
while on placebo increased from 89.5 % ± 8.9 to
92.2 % ± 3.7 (4.0 %). This represents an unclear change
between time points (2.7 % ± 6.8). Comparison of vol-
untary activation from pre-Visit 2 to post-Visit 2 was
unclear (0.26 % ± 4.7), as was post-Visit 1 to post-Visit
2 (0.050 % ± 3.4).
Performance measures
Changes from Visit 1 to Visit 2 are shown in Table 2 to
examine both raw differences and interpreted percent
changes. Both groups have similar performances in Visit
1, showing homogeneity of the sample population.
Change in the number of repetitions of back squat
was compared before and after supplementation. From
pre-testing 10RM determination to Visit 1, there was an
increase of 3 ± 4 and 2 ± 2 repetitions performed by the
N-3 PUFA and placebo group respectfully.
A change in performance was measured in the Win-
gate test. The N-3 PUFA group Wingate power drop
was lower from Visit 1 to Visit 2, while the PLA group
showed an increase in fatigue. This was very likely bene-
ficial (4.76 ± 3.4 %; OR = 6870).
In the 250 kJ TT the N-3 PUFA group mean was
slower than the PLA group by 39.4 s. At Visit 2, the N-3
PUFA group decreased their time by 6.2 ± 131.6 s while
the PLA group increased by 22.9 ± 65.1 s. With N-3
PUFA supplementation 9 participants improved time
trial time by 105.7 ± 106.0 s, whereas 4 PLA participants
improved by 39.2 ± 75.8 s.Plasma fatty acid analysis
Gas-flame chromatography performed to determine
change in the percent composition of plasma fatty acids
between groups (Table 3). Plasma EPA increased in the
N-3 PUFA group with no change in PLA after supple-
mentation (p = 0.004). There was a trend for higher DPA
and DHA after supplementation (p = 0.087, p = 0.058).
Discussion
This present study sought to elucidate the effect of 21-
days of N-3 PUFA supplementation on neuromuscular
function and performance measures in well-trained male
athletes. To our knowledge this is the first study to
evaluate the effects of a N-3 PUFA supplement on ath-
letes while measuring changes in both neuromuscular
function and performance. This study found that N-3
PUFA supplementation increased muscle activation and
attenuated fatigue as assessed during a Wingate test
after maximal back squat exercise by reducing percent
power drop.
Neuromuscular function
The primary outcome of this study was change in MVC
force from pre-Visit −1 to pre-Visit 2. The N-3 PUFA
group had an unclear 4.1 % ± 6.6 increase in MVC force,
indicating that individuals can experience a beneficial or
harmful change. However, we did observe a 9 % increase
in VL EMG activation in the N-3 PUFA group compared
to baseline and a very likely beneficial 22.0 ± 20.0 in-
crease in muscle activation. These data suggest N-3
PUFA supplementation supported peripheral (neuro-
muscular junction to contractile apparatus) but not
Table 2 Performance measures Visit 1 and Visit 2 for the omega-3 supplementation (N-3 PUFA) and placebo groups. The differences
in mean change is given as a percent ± 90 % confidence limits and corresponding inference
Test N-3 PUFA Placebo ΔN-3 vs. Δ PLA
(% ±90 % CL)
Inference
Visit 1 Visit 2 Visit 1 Visit 2
Squat Jump (cm) 34.6 ± 7.7 34.7 ± 6.7 36.6 ± 3.1 38.0 ± 7.1 2.4 ± 9.3 Unclear
Counter Movement Jump (cm) 43.5 ± 9.4 43.6 ± 7.2 45.5 ± 4.7 45.7 ± 6.2 1.4 ± 1.4 Unclear
Push-ups 1 50 ± 14 51 ± 13 49 ± 13 51 ± 14 1 ± 5.8 Unclear
Push-ups 2 23 ± 11 24 ± 10 25 ± 10 27 ± 12 1 ± 6.6 Unclear
Back Squat 13 ± 4 15 ± 4 12 ± 2 15 ± 4 5 ± 19 Unclear
Wingate PP (W) 841.30 ± 160.50 838 ± 176.84 835 ± 136.65 847.26 ± 130.25 2.17 ± 4.7 Unclear
Wingate Average Power (W) 593.1 ± 95.78 599.7 ± 92.65 611.3 ± 90.69 616.1 ± 104.44 0.74 ± 2.9 Unclear
Wingate Power Drop (%) 54.8 ± 9.54 54.6 ± 10.33 49.1 ± 5.82 53.0 ± 5.46 4.76 ± 3.4 Very likely beneficial
250 kJ Time Trial (sec) 1133.2 ± 296.1 1126.9 ± 265.7 1093.8 ± 269.8 1116.7 ± 269.6 1.96 ± 4.8 Unclear
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lar adaptations. In comparison, Rodacki et al. [6] showed
that 2 g.d−1 fish oil N-3 PUFA supplementation for
90 days during resistance training in sedentary women
increased muscle activation and MVC force by ~50 %
over training only controls. Two differences between this
work and the present study was supplement duration
and dose of 90 days compared to 21 days and 2 g.d−1
compared to 1.1 g.d−1. Therefore, a longer supplementa-
tion period and/or a higher dose might be necessary for
the observed increase in muscle activation to translate
into a beneficial increase in muscle force in this highly
trained population. These results along with Rodacki
et al. [6] provide evidence of the effect N-3 PUFA sup-
plementation on neuromuscular function across the
training spectrum and suggest a beneficial relationship
between N-3 PUFA supplementation and neuromuscular
adaptations to training.
Neuromuscular fatigue
When we examined the neuromuscular fatigue assessed
by change from pre to post Visit 2, N-3 PUFA had a
mixed effect. Central neuromuscular fatigue was appar-
ent but not different between groups as MVC force was
~20 % lower in both groups and voluntary activationTable 3 Fatty acid composition (%) of plasma for the omega-3 supp
N-3 PUFA
Fatty acids Pre Post
EPA (20:5 n-3) 0.41 ± 0.16 0.68 ± 0.27*
DPA (22:5 n-3) 0.29 ± 0.092 0.35 ± 0.091
DHA (22:6 n-3) 1.61 ± 0.32 1.81 ± 0.43
α-Linolenic (18:3 n-3) 0.39 ± 0.12 0.38 ± 0.18
Linoleic (18:2 n-6) 21.68 ± 2.85 21.01 ± 1.89
Arachidonic (20:4 n-6) 8.00 ± 2.07 7.43 ± 1.69
*Significant group by time interaction. All values are mean ± SD percentages for the
data collected prior to 21-days of supplementation. Post, data collect after 21-day owas unchanged. Peripheral measures showed no differ-
ence in quadriceps rate of force development, while
EMD was lower, indicating a faster activation of the con-
tractile apparatus. Interestingly, N-3 PUFA VL EMG ac-
tivation in was 10 % lower compared to pre-Visit 2
testing suggesting peripheral neuromuscular fatigue. We
suggest that the N-3 group performed more work during
visit 2 as demonstrated by attenuated fatigue in the Win-
gate test and the unclear 1.96 % ± 4.8 difference in
250 kJ TT performance. Regardless, VL EMG at post-
Visit 2 returned to baseline levels, therefore we interpret
any potential harm with caution.
Performance changes
Over the 21-day intervention, all participants were
instructed to continue with their normal daily training.
This was an important aspect of the study intervention,
as results from Rodacki et al. [6] revealed N-3 PUFA
supplementation only enhanced neuromuscular function
during resistance training and not during normal activ-
ities of daily living. As expected, both groups showed
evidence of training adaptations during the supplemen-
tation period. In the neuromuscular assessment, MVC
RFD increased similarly between groups, while the num-
ber of back squat repetitions with 10RM weight waslementation (N-3 PUFA) and placebo groups
Placebo
Pre Post p
0.59 ± 0.34 0.49 ± 0.24 0.004
0.31 ± 0.095 0.30 ± 0.055 0.087
1.65 ± 0.45 1.56 ± 0.042 0.058
0.41 ± 0.10 0.36 ± 0.11 0.53
22.75 ± 3.67 21.93 ± 3.16 0.86
7.42 ± 1.93 7.03 ± 1.97 0.86
omega-3 supplementation group (N-3 PUFA) and placebo group (PLA). Pre,
f supplementation. Data are shown as mean ± SD
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spectively. The improvement in 10RM back squat repeti-
tions caused 4.76 % ± 3.4 higher fatigue during the
Wingate test in the placebo group. We did not observe
any change in peak or mean Wingate power between
visits, indicating no change in central neuromuscular
function, however, the attenuation of fatigue observed in
the N-3 group indicates maintained peripheral neuro-
muscular function. This finding is consistent with the
observed increase in muscle activation. Performance in
the 250 kJ time trial showed an unclear difference of
1.96 % ± 4.8 between N-3 PUFA and placebo. This meas-
ure was the most variable of the protocol as the partici-
pants were fatigued from previous tests. This was an
inherent challenge of our protocol, as we wanted to
measure the effect of N-3 s on all tests requiring all en-
ergy systems from power (ATP) to aerobic endurance.
Nevertheless, 50 % of participants on N-3 PUFA improved
time trial performance while only 33 % on placebo im-
proved. Future evaluation of N-3 PUFA supplementation
should focus on one or two of these areas to tease out the
effects, as the combination clearly increases variability of
results.
Mechanism of action
Our data indicates N-3 PUFA supplementation improved
peripheral neuromuscular function with an unclear effect
on central neuromuscular function. Animal model re-
search has shown N-3 PUFAs can increase acetylcholine
concentration and acetylcholinesterase activity at the
neuromuscular junction [7]. This could increase the speed
of action potential transmission across the neuromuscular
junction, thereby increasing muscle activation and EMG.
N-3 PUFA supplementation is suggested to alter cellu-
lar membrane composition and fluidity [7]. This may en-
hance nerve conduction through lower nerve resistance
or improved ion channel function from the regulation of
mitogen activated kinase transcription factors [23]. In
this study, N-3 PUFA supplementation may have altered
muscle membrane dynamics. This could have enhanced
muscle action potential conduction through the working
muscle. Altered membrane dynamics could have miti-
gated muscle damage resulting from the 10RM squat
test. A reduction in damage might explain the attenu-
ated Wingate test performance observed in the N-3
PUFA group. Similarly, reduced muscle damage could
maintain muscle action potential conduction, thereby
maintaining muscle excitation contraction coupling and
ultimately muscle force generating capacity [24].
Supplement duration
This study used a short-term supplementation period
(21-days), as findings could be applied to support athlete
adaptations during training camps or a pre-competitiontaper. Other studies with ergogenic application have
demonstrated positive results in terms of reducing post-
exercise inflammation [8], increasing muscle protein
synthesis [25] or adaptations to training [6] using sup-
plement periods of 4–12 weeks. While our supplementa-
tion period was shorter than other studies, it has been
shown that 7 days is sufficient to increase plasma EPA
concentrations [26] and attenuate muscle soreness from
eccentric exercise [27]. Furthermore, 14 and 21-days of
supplementation in humans [28] and pigs [9], was suffi-
cient to increase muscle N-3 PUFA concentration.
Our supplementation protocol used a realistic N-3 PUFA
supplement dose of 1115 mg.d−1 essential fatty acids,
compared to previous N-3 PUFA intervention studies using
arguably super-physiologic doses of 3000 – 8000 mg.d−1
[9, 25, 29, 28]. Therefore, we feel these results have a high
level of applicability to athletes and the training popula-
tion, as high doses of N-3 PUFA may not be tolerable by
individuals over the long term and also can be expensive.
This is one of the first exercise studies to use a seal oil
N-3 PUFA supplement in contrast to the more commonly
used fish oil N-3 PUFA. Seal oil N-3 PUFA supplementa-
tion is the sn-1/3 position of N-3 fats compared to the sn-
2 of fish oil. This difference has been shown to promote
more rapid digestion of seal oil N-3 leading to subsequent
higher incorporation into non-hepatic tissues [30]. Partici-
pants in this study ingested supplements in oil form to
allow for potential sublingual absorption of the sn-3 N-3
[14]. This method of uptake may have increased the total
bioavailable N-3 PUFAs as transit through the stomach
can increase oxidation [8] and ultimately enable greater
uptake into muscle and nervous tissue.
Strengths and limitations
Several limitations became apparent throughout this
study. Using participants from an endurance training
background but different sports, yielded differences in
athletic abilities. While triathletes excelled at the endur-
ance portions of the experiment (time trial), they had
more variability in the 10 RM squat test. It would be ad-
visable that future studies of a similar nature recruit ath-
letes from the same, or similar, athletic backgrounds and
focus on a specific energy system.
Conclusion
In conclusion, 21-days of N-3 PUFA supplementation
increased plasma EPA N-3 PUFA concentration. Neuro-
muscular function was improved through increased
muscle activation and sprint cycling performance was
maintained from attenuated Wingate percent power
drop. Our data provide a basis for further investigation
of the effects of N-3 PUFA supplementation on the
neuromuscular system and as an ergogenic aid for
trained individuals.
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